Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure

Cardiovascular Therapeutics

Volumn 27, Issue 3, 2009, Pages 187-193

  Chaggar, Parminder S ^a   Malkin, Chris J ^b   Shaw, Steven M ^a   Williams, Simon G ^a   Channer, Kevin S ^b  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Heart failure; Hormone; Metabolic; Therapeutics

Indexed keywords

ADRENALIN; ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; EPLERENONE; HYDROCORTISONE; IVABRADINE; METOPROLOL; MOXONIDINE; NORADRENALIN; PLACEBO; PRASTERONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; SPIRONOLACTONE; TESTOSTERONE;

ANDROGEN DEFICIENCY; CATABOLISM; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANABOLIC AGENTS; ANIMALS; CATECHOLAMINES; GLUCOCORTICOIDS; HEART; HEART FAILURE; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; NEUROSECRETORY SYSTEMS; STEROIDS;

EID: 68849113580     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00094.x     Document Type: Review

References (75)

1. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000 83 : 596 602.
2. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolicanabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997 96 : 526 534.
3. Obisesan TO, Toth MJ, Donaldson K, Gottlieb SS, Fisher ML, Vaitekevicius P, Poehlman ET. Energy expenditure and symptom severity in men with heart failure. Am J Cardiol 1996 77 : 1250 1252.
4. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990 323 : 236 241.
5. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989 80 : 299 305.
6. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJ, Oliver MF. Insulin resistance in chronic heart failure. Eur Heart J 1994 15 : 1528 1532.
7. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: Prevalence and detrimental impact on survival. Circulation 2006 114 : 1829 1837.
8. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997 349 : 1050 1053.
9. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005 26 : 384 416. (Pubitemid 40283098)
10. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990 82 : 1730 1736.
11. Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002 106 : 92 99.
12. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984 311 : 819 823.
13. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003 107 : 1278 1283.
14. Cohn JN. Sympathetic nervous system activity and the heart. Am J Hypertens 1989 2 : 353S 356S.
15. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 2000 35 : S1 S7.
16. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004 25 : 292 299.
17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999 353 : 9 13.
18. Effect of metoprolol CRXL in chronic heart failure: Metoprolol CRXL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999 353 : 2001 2007.
19. Fowler MB. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: Carvedilol in severe heart failure. Am J Cardiol 2004 93 : 35B 39B.
20. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001 344 : 1659 1667.
21. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003 362 : 7 13.
22. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet 2008 372 : 807 816.
23. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986 314 : 1547 1552.
24. Cohn JN, Pfeffer MA, Rouleau J, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003 5 : 659 667.
25. Cody RJ, Franklin KW, Kluger J, Laragh JH. Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril. Am J Med 1982 72 : 791 797.
26. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002 106 : 2454 2458.
27. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 345 : 1667 1675.
28. Cohen SA, Jondeau G, Beauvais F, Berdeaux A. Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail 2004 6 : 463 466.
29. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999 33 : 1364 1368.
30. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci (Lond) 1999 96 : 513 523.
31. Connolly CK, Wills MR. Plasma cortisol levels in heart failure. Br Med J 1967 2 : 25 26.
32. Guder G, Bauersachs J, Frantz S, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007 115 : 1754 1761.
33. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987 237 : 268 275.
34. Funder JW. Is aldosterone bad for the heart Trends Endocrinol Metab 2004 15 : 139 142.
35. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003 93 : 69 76.
36. Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 2005 70 : 347 351.
37. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 341 : 709 717.
38. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001 15 : 79 87.
39. Pitt B. Promise of mineralocorticoid receptor blockade in asymptomatic left ventricular dysfunction. Hypertension 2007 50 : 461 462.
40. Treatment of Preserved Cardiac function heart failure with an Aldosterone anTagonist (TOPCAT), 2006. http://www.topcatstudy.com.
41. Aldosterone receptor blockade in diastolic heart failure, 2005. http://www.herzzentrum-goettingen.de/forschung/1959-DEU-HTML.htm.
42. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur Heart J 2006 27 : 57 64.
43. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004 89 : 3313 3318.
44. Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail 2007 9 : 44 50.
45. Di Filippo C, Verza M, Coppola L, Rossi F, D'Amico M, Marfella R. Insulin resistance and postprandial hyperglycemia the bad companions in natural history of diabetes: Effects on health of vascular tree. Curr Diabetes Rev 2007 3 : 268 273.
46. Boudina S, Abel ED, Diabetic cardiomyopathy revisited. Circulation 2007 115 : 3213 3223.
47. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996 77 : 1017 1020.
48. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure. J Am Coll Cardiol 1997 30 : 527 532.
49. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005 46 : 1019 1026.
50. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 : 854 865.
51. Niebauer J, Pflaum CD, Clark AL, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998 32 : 393 397.
52. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone. J Am Coll Cardiol 2001 38 : 443 452.
53. Corbalan R, Acevedo M, Godoy I, Jalil J, Campusano C, Klassen J. Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. J Card Fail 1998 4 : 115 119.
54. Cuocolo A, Nicolai E, Colao A, et al. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: Assessment with radionuclide angiography. Eur J Nucl Med 1996 23 : 390 394.
55. Jorgensen JO, Thuesen L, Muller J, Ovesen P, Skakkebaek NE, Christiansen JS. Three years of growth hormone treatment in growth hormone-deficient adults: Near normalization of body composition and physical performance. Eur J Endocrinol 1994 130 : 224 228.
56. Lombardi G, Colao A, Ferone D, Marzullo P, Orio F, Longobardi S, Merola B. Effect of growth hormone on cardiac function. Horm Res 1997 48 (Suppl 4 38 42.
57. Volterrani M, Desenzani P, Lorusso R, d'Aloia A, Manelli F, Giustina A. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997 349 : 1067 1068. (Pubitemid 27158254)
58. Capaldo B, Lembo G, Rendina V, et al. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy. Eur Heart J 1998 19 : 623 627.
59. Genth-Zotz S, Zotz R, Geil S, Voigtlander T, Meyer J, Darius H. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: Effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 1999 99 : 18 21.
60. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996 334 : 809 814. (Pubitemid 26099602)
61. Jose VJ, Zechariah TU, George P, Jonathan V. Growth hormone therapy in patients with dilated cardiomyopathy: Preliminary observations of a pilot study. Indian Heart J 1999 51 : 183 185.
62. Isgaard J, Bergh CH, Caidahl K, Lomsky M, Hjalmarson A, Bengtsson BA. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998 19 : 1704 1711.
63. Donath MY, Sutsch G, Yan XW, et al. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab 1998 83 : 3177 3183.
64. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998 351 : 1233 1237.
65. Acevedo M, Corbalan R, Chamorro G, et al. Administration of growth hormone to patients with advanced cardiac heart failure: Effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol 2003 87 : 185 191.
66. Perrot A, Ranke MB, Dietz R, Osterziel KJ. Growth hormone treatment in dilated cardiomyopathy. J Card Surg 2001 16 : 127 131.
67. Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 2003 9 : 219 226.
68. Doehner W, Pflaum CD, Rauchhaus M, et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol 2001 145 : 727 735.
69. Jin H, Yang R, Gillett N, Clark RG, Ko A, Paoni NF. Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J Cardiovasc Pharmacol 1995 26 : 420 425.
70. Tivesten A, Bollano E, Caidahl K, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 2000 141 : 60 66.
71. Enomoto M, Nagaya N, Uematsu M, et al. Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci (Lond) 2003 105 : 431 435.
72. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999 341 : 785 792.
73. Rosenfeld RG, Wilson DM, Dollar LA, Bennett A, Hintz RL. Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. J Clin Endocrinol Metab 1982 54 : 1033 1038.
74. Hintz RL, Rosenfeld RG, Wilson DM, Bennett A, Finno J, McClellan B, Swift R. Biosynthetic methionyl human growth hormones is biologically active in adult man. Lancet 1982 1 : 1276 1279.
75. Bourguignon JP, Pierard GE, Ernould C, et al. Effects of human growth hormone therapy on melanocytic naevi. Lancet 1993 341 : 1505 1506.